Vireo Growth (VREOF) Cash from Financing Activities (2020 - 2026)

Vireo Growth (VREOF) reported Cash from Financing Activities of -$4.6 million for Q1 2026, down 411.11% on a YoY basis from $1.5 million in Q1 2025, and down 7.52% sequentially from -$4.3 million in Q4 2025.

Vireo Growth (VREOF) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Vireo Growth (VREOF) has 7 years of Cash from Financing Activities data on file, last reported at -$4.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Financing Activities fell 411.11% year-over-year to -$4.6 million; the trailing twelve-month figure through Mar 2026 stood at $14.7 million (down 84.38% YoY), and the FY2025 full-year result was $18.4 million, down 80.41% from the prior year.
  • Cash from Financing Activities retreated to -$4.6 million in Q1 2026, from -$4.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $93.4 million in Q4 2024 to a low of -$9.3 million in Q2 2025.
  • A 5-year average of $8.0 million and a median of $821721.0 in 2023 frame the typical range for Cash from Financing Activities.
  • Peak annual rise in Cash from Financing Activities reached 45862.26% in 2025, while the deepest fall reached 609.87% in 2025.
  • Tracing VREOF's Cash from Financing Activities over 5 years: stood at $245839.0 in 2022, then jumped by 1242.04% to $3.3 million in 2023, then surged by 2730.21% to $93.4 million in 2024, then sank by 104.58% to -$4.3 million in 2025, then decreased by 7.52% to -$4.6 million in 2026.
  • Business Quant data shows VREOF's Cash from Financing Activities at -$4.6 million in Q1 2026, -$4.3 million in Q4 2025, and $32.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 13.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1.48 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -65.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn -4.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -4.60 Mn
Mar 31, 2026 -4.60 Mn
Dec 31, 2025 -4.28 Mn
Dec 31, 2025 -4.28 Mn
Sep 30, 2025 32.90 Mn
Sep 30, 2025 32.90 Mn
Jun 30, 2025 -9.30 Mn
Jun 30, 2025 -9.30 Mn
Mar 31, 2025 -900,000.00
Mar 31, 2025 -900,000.00
Dec 31, 2024 93.38 Mn
Dec 31, 2024 93.38 Mn
Sep 30, 2024 -71,892.00
Sep 30, 2024 -71,892.00
Jun 30, 2024 1.82 Mn
Jun 30, 2024 1.82 Mn
Mar 31, 2024 -1.12 Mn
Mar 31, 2024 -1.12 Mn
Dec 31, 2023 3.30 Mn
Dec 31, 2023 3.30 Mn